Genomictree Inc.

228760KOSDAQResearch and development

Genomictree Inc. (228760, KOSDAQ) reported KRW 4bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
20233-17-9133125Consolidated
20242-15-10131124Consolidated
20254-11-9121115Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
2023-506.2%-263.5%94.1%-7.2%
2024-648.2%-439.8%95.1%-8.4%
2025-300.5%-242.7%95.5%-7.9%

Revenue moved 10% between 2023 and 2025.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 262bn
Close priceKRW 10,530
Listed shares24,859,202
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

Workforce — a side measure, not the main one

Employees (2025)76
Women43 (56.6%)
Average tenure5.5 years
Annual pay, menKRW 67,545,455
Annual pay, womenKRW 39,790,698
Pay ratio, women to men58.9%

Other companies in Research and development

63 listed companies file under this classification. Showing 12.

See the whole Research and development list →